Restructuring of erythropoiesis and immune status in hypotrophic calves with comorbid pathologies based on the use of aminoseleferon-B

Abstract

The article presents the results of comparative therapeutic efficacy of a complex biogenic drug aminoseleferon-B based on recombinant interferons on Holstein calves with hypotrophy and comorbid pathology (anemia, immunodeficiency) in the neonatal period. According to the principle of pairanalogues, four groups of 6 individuals (hypotopic calves with comorbid pathology) were formed and the fifth – 6 normotrophic calves. The calves of the first experimental group were administered aminoseleton, the calves of the second experimental group - biferon-B, the calves of the third experimental group - the drug aminoseleferon-B. The drugs were administered subcutaneously, three times on days 1, 3 and 30 at a dose of 1 ml per 10 kg of animal weight. The calves of the fourth experimental group - negative control and the calves of the fifth group - positive control, the studied drugs were not used. The use of aminoseleferon-B leads to an earlier stabilization (on day 7 of our studies) of the morphological and immunological blood composition, whereas in the comparison groups, the studied indicators were optimized on day 30. In the animals of the 3rd experimental group, the level of erythrocytes increased by 9.3% and 6.4% compared to those in hypotrophic calves, a similar pattern was noted in the amount of total hemoglobin - increased by 13.7% and 7.7%. Humoral and cellular links of nonspecific protection were restored in the calves of the 3rd experimental group, due to normalization of serum compliment, lysozyme and bacterial activity, phagocytic index and number. The use of aminoseleferon-B in the treatment of polymorbid pathology (anemia, immunodeficiency) in calves with hypotrophy has a pathogenetically mediated mechanism of action and a pronounced anti-anemic and immunomodulatory effect that together improves the state of the calves body during early neonatal adaptation.